secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001140361-24-028247
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports positive Phase 3 results for donidalorsen in HAE; 81% attack reduction vs placebo
--------------------------------------------------------------------------------

- Donidalorsen met primary endpoint: 81% lower monthly HAE attack rate with Q4W dosing vs placebo (p<0.001) over 24 weeks.
- OASISplus OLE showed continued improvement: 93% (Q4W) and 92% (Q8W) attack rate reduction from baseline after one year.
- Switch cohort: patients switching from prior prophylactic to donidalorsen had 62% further reduction in mean monthly attack rates; 84% preferred donidalorsen.
- Donidalorsen was well-tolerated; no related serious TEAEs. Injection site reactions most common AE.
- Ionis plans to file NDA with FDA this year; Otsuka preparing MAA in Europe for donidalorsen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124028247/0001140361-24-028247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124028247/ef20030319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-028247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer